Early Detection and Screening of Hematological Malignancies - SANGUINE

This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions \[smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)\], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)\*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease. \*Patients with a diagnosis of acute promyelocytic leukemia (APL) are not included

Inclusion Criteria: General criteria for all study populations: 1. Male and female subjects ≥18 years of age 2. Ability to understand and willingness to sign a written informed consent document. For Patients with hematological malignancies: 1\. Patients who have been diagnosed, have measurable disease, and/or are being monitored/followed up due to one of the following conditions: MM, pre-MM conditions (SMM and MGUS), HL, DLBCL, FL, MZL, AML, MDS that did not yet undergo any treatment. NOTE: Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, who were treated for their primary disease (FL/MZL/MDS/MPN) before study enrollment, are eligible. For subjects at risk for developing the investigated hematological malignancies: 1. First-degree relatives; AND /OR 2. Elderly subjects ≥ 65 years of age. Exclusion Criteria: 1. Patients/subjects with current co-diagnosis of another type of cancer; 2. Patients/subjects with a known active or prior cancer (other than defined as study population), occurring within the last 2 years (even if considered to be in complete remission). Patients/subjects with non- melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; 3. Patients with a diagnosis of acute promyelocytic leukemia (APL) 4. Patients/subjects with active inflammatory autoimmune disease that requires treatment with immunosuppressive/ immunomodulation agents; 5. Patients/subjects with known human immunodeficiency virus (HIV) positive; 6. Patients/subjects with known active Hepatitis A/B/C or past hepatitis C; 7. Subjects that are likely to be noncompliant with the protocol, or felt to be unsuitable by the investigator for any other reason.